Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Research » 46th Annual Clinical Oncology Society of Australia (COSA) Meeting

46th Annual Clinical Oncology Society of Australia (COSA) Meeting

  • November 28, 2019

COSA held its 46th ASM in Adelaide 12 – 14 November 2019. There was an excellent attendance of multidisciplinary practitioners at the conference which was themed “Putting Precision and Personalisation into Practice”. COSA membership is diverse and the ASM celebrates this diversity with the depth of presentations by Clinicians, Researchers, Nurse, Pharmacists and Allied Health Professionals. There was a strong focus on Digital Technology to ensure comprehensive collection and utilization of data and also the impact of distance for cancer care. Another session was in the form of an MDT case discussion titled “A couple armed with an iPad” which covered gender issues, couples, sexuality, age and medicinal cannabis.

The Unicorn Foundation team attended the ASM. Over the three days there were sessions entitled “The Best of the Orals”, which saw the presented abstracts which had been submitted. Our CEO Simone, presented one of our current projects which is “Assessing the gaps in experience and knowledge of Australian Primary Health Care Professionals (GPs) in treating and caring for the increasing number of neuroendocrine tumour (NET) patients“. In this same session there was a presentation about – “Facilitating effective family carer engagement in cancer care – Development of education modules”.

On the final day the Plenary session was “Personalising cancer care at the population level: Beyond age and gender”. This presentation looked at cancer epidemiology across age spectrums (incidence, prevalence, burden and issues of disease, What about Race?, the emergence of youth cancer as a unique model of care and older cancer patients – the evolution of geriatric oncology and palliative care). Again this session was very thought provoking, taking into account the diversity of cancer patients and their needs. In the afternoon we had the privilege of an intimate Q&A and a performance by Kirk Pengilly (INXS band member) who talked about his cancer experience.

Meetings such as this ASM, are forums for updating and gaining knowledge of research and improvements in care. It also is a time to meet with International speakers and national colleagues to collaborate and share our work and plan for the future of cancer care.

Report by Meredith Cummins (UF Project Officer)

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

5HIAA Urine Collection Instructions for Patients

June 23, 2022

Donor Report 2021/2022

June 21, 2022

Cancer Nurses Society of Australia 24th Annual Congress

June 18, 2022

The Future of Precision Oncology in Nuclear Medicine – Report

June 16, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousClinical Trials and Neuroendocrine Tumours
NextNeuroEndocrine Cancer Australia present 6 scientific abstracts at ENETs 2020Next

Related Posts

5HIAA Urine Collection Instructions for Patients

Your doctor may order you to do a 5HIAA 24 hour urine test. Please click below to see the downloadable instruction sheet. Previously there were

Donor Report 2021/2022

It is with heartfelt gratitude that we thank our kind donors who enable us to continue to do what we do. We encourage you to

Cancer Nurses Society of Australia 24th Annual Congress

The 24th Cancer Nurses Society of Australia’s  (CNSA) Annual Congress took place at Brisbane Convention Centre Thursday 16 June to Saturday 18 June 2022. The

The Future of Precision Oncology in Nuclear Medicine – Report

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies
Menu
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
Menu
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
Menu
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
Menu
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative